Internal Blood Cancer Program(s)

About Chimera Bioengineering

Chimera Bioengineering is pioneering a novel approach to cell therapy by developing CAR-T cells with precisely controlled genetic programming. Their core technology, the GOLD PLATFORM™, includes components like MERCURY™ for tuning CAR expression and GOLD CONTROL™ for regulating therapeutic payloads, addressing key challenges of insufficient activity and excessive toxicity in current cell therapies. The company is independently advancing several solid tumor and blood cancer programs toward clinical trials while seeking strategic collaborations to validate and expand its platform. Their mission is to transform the promise of cell therapies into effective, safe treatments that restore dignity to cancer patients.

Therapeutic Areas

Other Blood Cancers Drugs